Although now well understood, a pattern of resistance to ALK TKI treatment in NB is emerging, and the underlying mechanisms include: mutation of ALK itself [35], reactivation of the RAS-MAPK pathway [36], epigenetic reprogramming [37], and gene amplification of cyclin-dependent kinases (CDKs) and other RTKs [38]. Here, ALK is linked to neuroblastoma.